Antigen-specific immunotherapy for acute myeloid leukemia: where are we now, and where do we go from here?

Expert Review of Hematology
Armin Rashidi, Roland B Walter

Abstract

Antigen-specific immunotherapies have long been pursued as a means to improve the outcomes of patients with acute myeloid leukemia (AML). Success thus far has been limited, and many therapeutics have either been ineffective in the clinic or have an uncertain impact on patient outcomes. Only the CD33 antibody-drug conjugate gemtuzumab ozogamicin provided benefit in randomized studies. Here, we briefly review where we currently are with antigen-specific AML immunotherapy and where we might go from here. Besides the exploration of novel target antigens, ongoing preclinical and clinical efforts aim to improve existing immunotherapy modalities and focus on developing novel therapeutics such as bispecific antibodies and gene-modified immune effector cells. Ultimately, clinical studies need to address the question of ideal target(s) in AML, a disease of great antigenic diversity, and clarify how the upcoming immunotherapeutics should be best used and what level of supportive care is required for their safe administration.

References

Mar 22, 2002·Nature Reviews. Cancer·P Carter
Sep 26, 2006·Nature Medicine·Liqing JinJohn E Dick
Sep 2, 2008·Seminars in Hematology·Donald Small
Jun 11, 2009·Cancer Research·Patrick A Baeuerle, Carsten Reinhardt
Oct 7, 2009·Expert Review of Vaccines·Michael SchmittAnita Schmitt
Apr 29, 2010·Cancer Biotherapy & Radiopharmaceuticals·Roland B WalterJohn M Pagel
Jul 16, 2010·Proceedings of the National Academy of Sciences of the United States of America·Viggo F Van TendelooZwi N Berneman
Sep 23, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Todd L RosenblatJoseph G Jurcic
Nov 30, 2010·Cell Stem Cell·Yoshikane KikushigeKoichi Akashi
Feb 17, 2011·Expert Review of Hematology·Gheath Alatrash, Jeffrey J Molldrem
Jan 31, 2012·Blood·Roland B WalterIrwin D Bernstein
Mar 20, 2012·Cell·Louis M WeinerCasey W Shuptrine
Mar 28, 2012·Cancer Cell International·Ana M Soto, Carlos Sonnenschein
Sep 5, 2012·The Journal of Experimental Medicine·Alexandre P A TheocharidesJean C Y Wang
Dec 6, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Michelle R KuhnePina M Cardarelli
Feb 6, 2013·Theranostics·Amnon Peled, Sigal Tavor
Feb 27, 2013·Cancer Imaging : the Official Publication of the International Cancer Imaging Society·Helmut SchoellnastStephen B Solomon
Mar 15, 2013·Science Translational Medicine·Tao DaoDavid A Scheinberg
Apr 6, 2013·Immunotherapy·Joseph G Jurcic
May 28, 2013·International Journal of Hematology·Akihiro Takeshita
Jun 12, 2013·Frontiers in Bioscience (Landmark Edition)·Andrew J CowanRoland B Walter
Jul 9, 2013·Molecular Therapy : the Journal of the American Society of Gene Therapy·David S RitchieH Miles Prince
Jul 23, 2013·Blood Reviews·Anna MartnerKristoffer Hellstrand

❮ Previous
Next ❯

Citations

Feb 26, 2016·Expert Review of Hematology·Naval DaverFarhad Ravandi
Apr 7, 2017·Pediatric Blood & Cancer·John Anderson
Mar 15, 2018·Expert Opinion on Investigational Drugs·Roland B Walter
Jan 11, 2018·British Journal of Haematology·Armin RashidiNelli Bejanyan
Nov 4, 2017·Current Hematologic Malignancy Reports·Kristen Pettit, Olatoyosi Odenike
May 26, 2018·Bone Marrow Transplantation·Nicola GökbugetDavid Avigan
Mar 2, 2021·Hematology/oncology Clinics of North America·Naveen PemmarajuSrdan Verstovsek

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Antibody Engineering

Antibody engineering technologies are constantly advancing to improve the clinical effectiveness of monoclonal and bispecific antibodies. Discover the latest research on Antibody Engineering here.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

© 2022 Meta ULC. All rights reserved